Suppr超能文献

器官移植受者严重急性呼吸综合征冠状病毒 2 再感染的纵向免疫分析。

Longitudinal Immune Profiling of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection in a Solid Organ Transplant Recipient.

机构信息

Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.

Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.

出版信息

J Infect Dis. 2022 Feb 1;225(3):374-384. doi: 10.1093/infdis/jiab553.

Abstract

BACKGROUND

The underlying immunologic deficiencies enabling severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection are currently unknown. We describe deep longitudinal immune profiling of a transplant recipient hospitalized twice for coronavirus disease 2019 (COVID-19).

METHODS

A 66-year-old male renal transplant recipient was hospitalized with COVID-19 March 2020 then readmitted to the hospital with COVID-19 233 days after initial diagnosis. Virologic and immunologic investigations were performed on samples from the primary and secondary infections.

RESULTS

Whole viral genome sequencing and phylogenetic analysis revealed that viruses causing both infections were caused by distinct genetic lineages without evidence of immune escape mutations. Longitudinal comparison of cellular and humoral responses during primary SARS-CoV-2 infection revealed that this patient responded to the primary infection with low neutralization titer anti-SARS-CoV-2 antibodies that were likely present at the time of reinfection.

CONCLUSIONS

The development of neutralizing antibodies and humoral memory responses in this patient failed to confer protection against reinfection, suggesting that they were below a neutralizing titer threshold or that additional factors may be required for efficient prevention of SARS-CoV-2 reinfection. Development of poorly neutralizing antibodies may have been due to profound and relatively specific reduction in naive CD4 T-cell pools. Seropositivity alone may not be a perfect correlate of protection in immunocompromised patients.

摘要

背景

目前尚不清楚导致严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 再感染的潜在免疫缺陷。我们描述了一名因 2019 年冠状病毒病 (COVID-19) 两次住院的移植受者的深度纵向免疫分析。

方法

一名 66 岁男性肾移植受者于 2020 年 3 月因 COVID-19 住院,初次诊断后 233 天因 COVID-19 再次入院。对原发性和继发性感染的样本进行了病毒学和免疫学调查。

结果

全病毒基因组测序和系统发育分析显示,导致两次感染的病毒均由不同的遗传谱系引起,没有免疫逃逸突变的证据。在初次 SARS-CoV-2 感染期间对细胞和体液反应的纵向比较表明,该患者对初次感染的反应是低中和效价的抗 SARS-CoV-2 抗体,这些抗体可能在再次感染时存在。

结论

该患者体内中和抗体和体液记忆反应的发展未能提供针对再感染的保护,这表明它们的中和效价低于阈值,或者可能需要其他因素才能有效预防 SARS-CoV-2 的再感染。中和抗体产生不良可能是由于幼稚 CD4 T 细胞库严重且相对特异性减少所致。在免疫功能低下的患者中,血清阳性本身可能不是保护的完美相关因素。

相似文献

2
Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient.
medRxiv. 2021 Mar 26:2021.03.24.21253992. doi: 10.1101/2021.03.24.21253992.
3
Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient.
Res Sq. 2021 May 5:rs.3.rs-405958. doi: 10.21203/rs.3.rs-405958/v1.
4
Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection.
J Adv Res. 2021 Jul;31:49-60. doi: 10.1016/j.jare.2020.12.013. Epub 2021 Jan 5.
6
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
EBioMedicine. 2021 Sep;71:103561. doi: 10.1016/j.ebiom.2021.103561. Epub 2021 Aug 27.
9
SARS-CoV-2 reinfection in a cancer patient with a defective neutralizing humoral response.
J Med Virol. 2021 Dec;93(12):6444-6446. doi: 10.1002/jmv.27200. Epub 2021 Jul 20.
10
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection.
Nat Rev Immunol. 2021 Jun;21(6):395-404. doi: 10.1038/s41577-021-00550-x. Epub 2021 Apr 29.

引用本文的文献

1
Clinical and immunological insights into SARS-CoV-2 reinfection: a propensity score-matched cohort study.
BMC Infect Dis. 2025 Aug 1;25(1):970. doi: 10.1186/s12879-025-11398-0.
2
Laboratory Diagnosis for SARS-CoV-2 Infection.
Infect Dis Clin North Am. 2022 Jun;36(2):327-347. doi: 10.1016/j.idc.2022.02.002.
3
Reinfection in patients with COVID-19: a systematic review.
Glob Health Res Policy. 2022 Apr 29;7(1):12. doi: 10.1186/s41256-022-00245-3.

本文引用的文献

2
Protein-Based Immunome Wide Association Studies (PIWAS) for the Discovery of Significant Disease-Associated Antigens.
Front Immunol. 2021 Apr 27;12:625311. doi: 10.3389/fimmu.2021.625311. eCollection 2021.
3
Evaluation of the analytical performance and specificity of a SARS-CoV-2 transcription-mediated amplification assay.
J Virol Methods. 2021 Aug;294:114182. doi: 10.1016/j.jviromet.2021.114182. Epub 2021 May 10.
4
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
Cell. 2021 Apr 29;184(9):2372-2383.e9. doi: 10.1016/j.cell.2021.03.013. Epub 2021 Mar 12.
6
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
7
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.
N Engl J Med. 2021 Feb 11;384(6):533-540. doi: 10.1056/NEJMoa2034545. Epub 2020 Dec 23.
8
B cell depletion therapies in autoimmune disease: advances and mechanistic insights.
Nat Rev Drug Discov. 2021 Mar;20(3):179-199. doi: 10.1038/s41573-020-00092-2. Epub 2020 Dec 15.
10
Long-term SARS-CoV-2 RNA shedding and its temporal association to IgG seropositivity.
Cell Death Discov. 2020 Dec 2;6(1):138. doi: 10.1038/s41420-020-00375-y.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验